IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

Rhea-AI Summary

IO Biotech (Nasdaq: IOBT) announced two poster presentations at the ASCO Annual Meeting 2022, showcasing clinical trials involving its investigational agent IO102-IO103 in combination with pembrolizumab for metastatic solid tumors and melanoma. The first is a Phase 3 trial on untreated, unresectable melanoma, while the second is a Phase 2 study targeting metastatic non-small cell lung cancer and other cancers. IO102-IO103 aims to counter immunosuppressive mechanisms through IDO and PD-L1 targeting. The presentations will occur from June 5-6, 2022, in Chicago.

Positive

• Two poster presentations at ASCO 2022 highlight clinical trials for IO102-IO103.
• Focus on combination therapy with pembrolizumab, potentially enhancing treatment efficacy.
• IO102-IO103 targets critical immunosuppressive proteins IDO and PD-L1.

Negative

• None.

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today two poster presentations highlighting clinical trials in progress with IO102-IO103 as an investigational agent in combination with pembrolizumab in metastatic solid tumors and in untreated, unresectable or metastatic melanoma at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022. The meeting will be held in-person and virtually June 3-7, 2022 in Chicago.

Presentation Details

Poster Title: Randomized Phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma
Abstract Number: TPS9589
Session: June 6, 2022 at 1:15 PM - 4:15 PM Hall A-14397
Presenter: Alexander Eggermont, M.D., Ph.D.

Poster Title: Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC)
Abstract Number: TPS2699
Session: June 5, 2022 from 8:00 - 11:00 AM Hall A-14355
Presenter: Jonathan Riess, M.D.

About IO102-IO103

IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates.  IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).

For further information, please visit www.iobiotech.com

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

Company Contact:
Mai-Britt Zocca, Ph.D.
President and CEO
IO Biotech, Inc.
mz@iobiotech.com

Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com

Media Contact:
Raena Mina, Ph.D.
LifeSci Communications
646-606-1438
rmina@lifescicomms.com

FAQ

What is IO Biotech presenting at ASCO 2022?

IO Biotech is presenting two clinical trials of IO102-IO103 in combination with pembrolizumab for metastatic melanoma and other solid tumors.

When is the ASCO Annual Meeting 2022?

The ASCO Annual Meeting 2022 will be held from June 3 to June 7, 2022, in Chicago.

What clinical trials are being presented by IO Biotech?

The trials include a Phase 3 trial for melanoma and a Phase 2 study for non-small cell lung cancer and other cancers.

What is the focus of IO102-IO103 treatments?

IO102-IO103 aims to target immunosuppressive mechanisms by inhibiting IDO and PD-L1 proteins.

What company symbol is associated with IO Biotech?

The stock symbol for IO Biotech is IOBT.